# Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops

> **NCT01434888** · PHASE1 · COMPLETED · sponsor: **Santen Oy** · enrollment: 15 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Preservative free tafluprost 0.0015% eye drops
- **DRUG:** Preservative free timolol 0.5% eye drops
- **DRUG:** Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops

## Key facts

- **NCT ID:** NCT01434888
- **Lead sponsor:** Santen Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2012-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01434888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01434888, "Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01434888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*